Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Rheumatology International
Published in: Rheumatology International 5/2010

01-03-2010 | Review

Complementary and alternative medicine use in rheumatoid arthritis: proposed mechanism of action and efficacy of commonly used modalities

Authors: Petros Efthimiou, Manil Kukar

Published in: Rheumatology International | Issue 5/2010

Login to get access

Abstract

Complementary and alternative medicine (CAM) has become popular in patients with Rheumatoid arthritis (RA) worldwide. The objective of this study is to systematically review the proposed mechanisms of action and currently available evidence supporting the efficacy of CAM modalities in relieving signs and symptoms of RA. The prevalence of CAM usage by RA patients is anywhere from 28% to 90%. Many published studies on CAM are based on animal models of RA and there is often insufficient evidence for the efficacy of CAM modalities in RA. The existing evidence suggests that some of the CAM modalities, such as acupuncture, herbal medicines, dietary omega-3 fatty acids, vitamins, and pulsed electromagnetic field show promising efficacy in reducing pain. While the use of CAM modalities for the treatment of RA continues to increase, rigorous clinical trials examining their efficacy are necessary to validate or refute the clinical claims made for CAM therapies.
Literature
1.
Barnes PM et al (2004) Complementary and alternative medicine use among adults: United States, 2002. Adv Data 343:1–19PubMed
2.
Brune K (2004) Safety of anti-inflammatory treatment—new ways of thinking. Rheumatology (Oxford) 43(Suppl 1):i16–i20
3.
Soeken KL, Miller SA, Ernst E (2003) Herbal medicines for the treatment of rheumatoid arthritis: a systematic review. Rheumatology (Oxford) 42(5):652–659
4.
Astin JA (1999) Use of alternative medicine by women with breast cancer. N Engl J Med 341(15):1156 Author reply 1156–1157PubMed
5.
Lawrence RC et al (1998) Estimates of the prevalence of arthritis and selected musculoskeletal disorders in the United States. Arthritis Rheum 41(5):778–799PubMed
6.
Chikanza IC et al (1998) Why do we need new treatments for rheumatoid arthritis? J Pharm Pharmacol 50(4):357–369PubMed
7.
Taibi DM, Bourguignon C (2003) The role of complementary and alternative therapies in managing rheumatoid arthritis. Fam Community Health 26(1):41–52PubMed
8.
Soeken KL (2004) Selected CAM therapies for arthritis-related pain: the evidence from systematic reviews. Clin J Pain 20(1):13–18PubMed
9.
Rosted P, Warnakulasuriya S (2005) A survey on the uses of acupuncture by a group of UK dentists. Br Dent J 198(3):139–143PubMed
10.
Vickers A, Zollman C (1999) ABC of complementary medicine. Acupuncture. BMJ 319(7215):973–976PubMed
11.
Lao L (1996) Acupuncture techniques and devices. J Altern Complement Med 2(1):23–25PubMed
12.
Zanette Sde A et al (2008) A pilot study of acupuncture as adjunctive treatment of rheumatoid arthritis. Clin Rheumatol 27(5):627–635PubMed
13.
Tam LS et al (2007) Acupuncture in the treatment of rheumatoid arthritis: a double-blind controlled pilot study. BMC Complement Altern Med 7:35PubMed
14.
Yim YK et al (2007) Electro-acupuncture at acupoint ST36 reduces inflammation and regulates immune activity in collagen-induced arthritic mice. Evid Based Complement Alternat Med 4(1):51–57PubMed
15.
Holmdahl R et al (1990) Type II collagen autoimmunity in animals and provocations leading to arthritis. Immunol Rev 118:193–232PubMed
16.
Weyand CM, Fulbright JW, Goronzy JJ (2003) Immunosenescence, autoimmunity, and rheumatoid arthritis. Exp Gerontol 38(8):833–841PubMed
17.
Choy EH et al (2002) Therapeutic benefit of blocking interleukin-6 activity with an anti-interleukin-6 receptor monoclonal antibody in rheumatoid arthritis: a randomized, double-blind, placebo-controlled, dose-escalation trial. Arthritis Rheum 46(12):3143–3150PubMed
18.
Elliott MJ et al (1993) Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor alpha. Arthritis Rheum 36(12):1681–1690PubMed
19.
Miossec P (2004) An update on the cytokine network in rheumatoid arthritis. Curr Opin Rheumatol 16(3):218–222PubMed
20.
Cook AD et al (2004) Antibodies against the CB10 fragment of type II collagen in rheumatoid arthritis. Arthritis Res Ther 6(5):R477–R483PubMed
21.
Panayi GS, Corrigall VM, Pitzalis C (2001) Pathogenesis of rheumatoid arthritis. The role of T cells and other beasts. Rheum Dis Clin North Am 27(2):317–334PubMed
22.
Silverman GJ, Carson DA (2003) Roles of B cells in rheumatoid arthritis. Arthritis Res Ther 5(Suppl 4):S1–S6PubMed
23.
Dorner T, Burmester GR (2003) The role of B cells in rheumatoid arthritis: mechanisms and therapeutic targets. Curr Opin Rheumatol 15(3):246–252PubMed
24.
Lee DM, Weinblatt ME (2001) Rheumatoid arthritis. Lancet 358(9285):903–911PubMed
25.
Firestein GS (2003) Evolving concepts of rheumatoid arthritis. Nature 423(6937):356–361PubMed
26.
David J et al (1999) The effect of acupuncture on patients with rheumatoid arthritis: a randomized, placebo-controlled cross-over study. Rheumatology (Oxford) 38(9):864–869
27.
Lee JD et al (2005) An overview of bee venom acupuncture in the treatment of arthritis. Evid Based Complement Alternat Med 2(1):79–84PubMed
28.
Kwon YB et al (2001) Bee venom injection into an acupuncture point reduces arthritis associated edema and nociceptive responses. Pain 90(3):271–280PubMed
29.
Borchers AT et al (2000) Inflammation and native american medicine: the role of botanicals. Am J Clin Nutr 72(2):339–347PubMed
30.
Marok R et al (1996) Activation of the transcription factor nuclear factor-kappaB in human inflamed synovial tissue. Arthritis Rheum 39(4):583–591PubMed
31.
Winyard PG, Blake DR (1997) Antioxidants, redox-regulated transcription factors, and inflammation. Adv Pharmacol 38:403–421PubMed
32.
Mix KS et al (2001) A synthetic triterpenoid selectively inhibits the induction of matrix metalloproteinases 1 and 13 by inflammatory cytokines. Arthritis Rheum 44(5):1096–1104PubMed
33.
Siddiqui IA et al (2004) Antioxidants of the beverage tea in promotion of human health. Antioxid Redox Signal 6(3):571–582PubMed
34.
Curtis CL et al (2004) Biological basis for the benefit of nutraceutical supplementation in arthritis. Drug Discov Today 9(4):165–172PubMed
35.
Singh R et al (2002) Epigallocatechin-3-gallate inhibits interleukin-1beta-induced expression of nitric oxide synthase and production of nitric oxide in human chondrocytes: suppression of nuclear factor kappaB activation by degradation of the inhibitor of nuclear factor kappaB. Arthritis Rheum 46(8):2079–2086PubMed
36.
Ahmed S et al (2002) Green tea polyphenol epigallocatechin-3-gallate inhibits the IL-1 beta-induced activity and expression of cyclooxygenase-2 and nitric oxide synthase-2 in human chondrocytes. Free Radic Biol Med 33(8):1097–1105PubMed
37.
Singh R et al (2003) Epigallocatechin-3-gallate selectively inhibits interleukin-1beta-induced activation of mitogen activated protein kinase subgroup c-Jun N-terminal kinase in human osteoarthritis chondrocytes. J Orthop Res 21(1):102–109PubMed
38.
Vincenti MP, Brinckerhoff CE (2001) The potential of signal transduction inhibitors for the treatment of arthritis: is it all just JNK? J Clin Invest 108(2):181–183PubMed
39.
Ahmed S et al (2004) Green tea polyphenol epigallocatechin-3-gallate (EGCG) differentially inhibits interleukin-1 beta-induced expression of matrix metalloproteinase-1 and -13 in human chondrocytes. J Pharmacol Exp Ther 308(2):767–773PubMed
40.
Adcocks C, Collin P, Buttle DJ (2002) Catechins from green tea (Camellia sinensis) inhibit bovine and human cartilage proteoglycan and type II collagen degradation in vitro. J Nutr 132(3):341–346PubMed
41.
Vankemmelbeke MN et al (2003) Selective inhibition of ADAMTS-1, -4 and -5 by catechin gallate esters. Eur J Biochem 270(11):2394–2403PubMed
42.
Haqqi TM et al (1999) Prevention of collagen-induced arthritis in mice by a polyphenolic fraction from green tea. Proc Natl Acad Sci USA 96(8):4524–4529PubMed
43.
Spivey AC, Weston M, Woodhead S (2002) Celastraceae sesquiterpenoids: biological activity and synthesis. Chem Soc Rev 31(1):43–59PubMed
44.
Guo YQ et al (2004) Sesquiterpene esters from the fruits of Celastrus orbiculatus. Chem Pharm Bull (Tokyo) 52(9):1134–1136
45.
Jin HZ et al (2002) Antiinflammatory constituents of Celastrus orbiculatus inhibit the NF-kappaB activation and NO production. J Nat Prod 65(1):89–91PubMed
46.
Min KR et al (1999) (−)−Epiafzelechin: cyclooxygenase-1 inhibitor and anti-inflammatory agent from aerial parts of Celastrus orbiculatus. Planta Med 65(5):460–462PubMed
47.
Westerheide SD et al (2004) Celastrols as inducers of the heat shock response and cytoprotection. J Biol Chem 279(53):56053–56060PubMed
48.
Nam NH (2006) Naturally occurring NF-kappaB inhibitors. Mini Rev Med Chem 6(8):945–951PubMed
49.
Appleton I, Tomlinson A, Willoughby DA (1996) Induction of cyclo-oxygenase and nitric oxide synthase in inflammation. Adv Pharmacol 35:27–78PubMed
50.
Tong L, Moudgil KD (2007) Celastrus aculeatus Merr. suppresses the induction and progression of autoimmune arthritis by modulating immune response to heat-shock protein 65. Arthritis Res Ther 9(4):R70PubMed
51.
Ulmansky R et al (2002) Resistance to adjuvant arthritis is due to protective antibodies against heat shock protein surface epitopes and the induction of IL-10 secretion. J Immunol 168(12):6463–6469PubMed
52.
Kim HR et al (2006) Antibody responses to mycobacterial and self heat shock protein 65 in autoimmune arthritis: epitope specificity and implication in pathogenesis. J Immunol 177(10):6634–6641PubMed
53.
Williams JE (2001) Review of antiviral and immunomodulating properties of plants of the Peruvian rainforest with a particular emphasis on Una de Gato and Sangre de Grado. Altern Med Rev 6(6):567–579PubMed
54.
Sandoval-Chacon M et al (1998) Antiinflammatory actions of cat’s claw: the role of NF-kappaB. Aliment Pharmacol Ther 12(12):1279–1289PubMed
55.
Sandoval M et al (2002) Anti-inflammatory and antioxidant activities of cat’s claw (Uncaria tomentosa and Uncaria guianensis) are independent of their alkaloid content. Phytomedicine 9(4):325–337PubMed
56.
Miller MJ et al (2001) Dietary antioxidants protect gut epithelial cells from oxidant-induced apoptosis. BMC Complement Altern Med 1:11PubMed
57.
Sandoval M et al (2000) Cat’s claw inhibits TNFalpha production and scavenges free radicals: role in cytoprotection. Free Radic Biol Med 29(1):71–78PubMed
58.
Muhammad I (2001) Investigation of Una De Gato I. 7-Deoxyloganic acid and 15N NMR spectroscopic studies on pentacyclic oxindole alkaloids from Uncaria tomentosa. Phytochemistry 57(5):781–785PubMed
59.
Mur E et al (2002) Randomized double blind trial of an extract from the pentacyclic alkaloid-chemotype of Uncaria tomentosa for the treatment of rheumatoid arthritis. J Rheumatol 29(4):678–681PubMed
60.
Piscoya J et al (2001) Efficacy and safety of freeze-dried cat’s claw in osteoarthritis of the knee: mechanisms of action of the species Uncaria guianensis. Inflamm Res 50(9):442–448PubMed
61.
Santa Maria A et al (1997) Evaluation of the toxicity of Uncaria tomentosa by bioassays in vitro. J Ethnopharmacol 57(3):183–187PubMed
62.
Gonzales GF et al (2003) Effect of Lepidium meyenii (Maca), a root with aphrodisiac and fertility-enhancing properties, on serum reproductive hormone levels in adult healthy men. J Endocrinol 176(1):163–168PubMed
63.
Gonzales GF et al (2002) Effect of Lepidium meyenii (MACA) on sexual desire and its absent relationship with serum testosterone levels in adult healthy men. Andrologia 34(6):367–372PubMed
64.
Gonzales GF et al (2001) Lepidium meyenii (Maca) improved semen parameters in adult men. Asian J Androl 3(4):301–303PubMed
65.
Miller MJ et al (2006) The chrondoprotective actions of a natural product are associated with the activation of IGF-1 production by human chondrocytes despite the presence of IL-1beta. BMC Complement Altern Med 6:13PubMed
66.
Fernandez-Celemin L et al (2002) Inhibition of muscle insulin-like growth factor I expression by tumor necrosis factor-alpha. Am J Physiol Endocrinol Metab 283(6):E1279–E1290PubMed
67.
De Benedetti F et al (2001) Effect of IL-6 on IGF binding protein-3: a study in IL-6 transgenic mice and in patients with systemic juvenile idiopathic arthritis. Endocrinology 142(11):4818–4826PubMed
68.
Tao X, Lipsky PE (2000) The Chinese anti-inflammatory and immunosuppressive herbal remedy Tripterygium wilfordii Hook F. Rheum Dis Clin North Am 26(1):29–50PubMed
69.
Qiu D, Kao PN (2003) Immunosuppressive and anti-inflammatory mechanisms of triptolide, the principal active diterpenoid from the Chinese medicinal herb Tripterygium wilfordii Hook f. Drugs R D 4(1):1–18PubMed
70.
Lin N, Sato T, Ito A (2001) Triptolide, a novel diterpenoid triepoxide from Tripterygium wilfordii Hook. f., suppresses the production and gene expression of pro-matrix metalloproteinases 1 and 3 and augments those of tissue inhibitors of metalloproteinases 1 and 2 in human synovial fibroblasts. Arthritis Rheum 44(9):2193–2200PubMed
71.
Liacini A, Sylvester J, Zafarullah M (2005) Triptolide suppresses proinflammatory cytokine-induced matrix metalloproteinase and aggrecanase-1 gene expression in chondrocytes. Biochem Biophys Res Commun 327(1):320–327PubMed
72.
Tao X et al (2002) Benefit of an extract of Tripterygium Wilfordii Hook F in patients with rheumatoid arthritis: a double-blind, placebo-controlled study. Arthritis Rheum 46(7):1735–1743PubMed
73.
Tao X et al (2001) A phase I study of ethyl acetate extract of the Chinese antirheumatic herb Tripterygium wilfordii hook F in rheumatoid arthritis. J Rheumatol 28(10):2160–2167PubMed
74.
Ahmed S et al (2005) Biological basis for the use of botanicals in osteoarthritis and rheumatoid arthritis: a review. Evid Based Complement Alternat Med 2(3):301–308PubMed
75.
Miller TE et al. (1993) Anti-inflammatory activity of glycogen extracted from Perna canaliculus (NZ green-lipped mussel). Agents Actions 38 Spec No:C139–C142
76.
Cobb CS, Ernst E (2006) Systematic review of a marine nutriceutical supplement in clinical trials for arthritis: the effectiveness of the New Zealand green-lipped mussel Perna canaliculus. Clin Rheumatol 25(3):275–284PubMed
77.
Mani S, Lawson JW (2006) In vitro modulation of inflammatory cytokine and IgG levels by extracts of Perna canaliculus. BMC Complement Altern Med 6:1PubMed
78.
Halpern GM (2000) Anti-inflammatory effects of a stabilized lipid extract of Perna canaliculus (Lyprinol). Allerg Immunol (Paris) 32(7):272–278
79.
Miller T, Wu H (1984) In vivo evidence for prostaglandin inhibitory activity in New Zealand green-lipped mussel extract. N Z Med J 97(757):355–357PubMed
80.
Lawson BR et al (2007) Immunomodulation of murine collagen-induced arthritis by N, N-dimethylglycine and a preparation of Perna canaliculus. BMC Complement Altern Med 7:20PubMed
81.
Aggarwal BB, Shishodia S (2004) Suppression of the nuclear factor-kappaB activation pathway by spice-derived phytochemicals: reasoning for seasoning. Ann N Y Acad Sci 1030:434–441PubMed
82.
Chainani-Wu N (2003) Safety and anti-inflammatory activity of curcumin: a component of tumeric (Curcuma longa). J Altern Complement Med 9(1):161–168PubMed
83.
Srivastava KC, Bordia A, Verma SK (1995) Curcumin, a major component of food spice turmeric (Curcuma longa) inhibits aggregation and alters eicosanoid metabolism in human blood platelets. Prostaglandins Leukot Essent Fatty Acids 52(4):223–227PubMed
84.
Ranjan D et al (2004) Curcumin inhibits mitogen stimulated lymphocyte proliferation, NFkappaB activation, and IL-2 signaling. J Surg Res 121(2):171–177PubMed
85.
Liacini A et al (2002) Inhibition of interleukin-1-stimulated MAP kinases, activating protein-1 (AP-1) and nuclear factor kappa B (NF-kappa B) transcription factors down-regulates matrix metalloproteinase gene expression in articular chondrocytes. Matrix Biol 21(3):251–262PubMed
86.
Schulze-Tanzil G et al (2004) Effects of curcumin (diferuloylmethane) on nuclear factor kappaB signaling in interleukin-1beta-stimulated chondrocytes. Ann N Y Acad Sci 1030:578–586PubMed
87.
Hong J et al (2004) Modulation of arachidonic acid metabolism by curcumin and related beta-diketone derivatives: effects on cytosolic phospholipase A(2), cyclooxygenases and 5-lipoxygenase. Carcinogenesis 25(9):1671–1679PubMed
88.
Wallace JM (2002) Nutritional and botanical modulation of the inflammatory cascade—eicosanoids, cyclooxygenases, and lipoxygenases—as an adjunct in cancer therapy. Integr Cancer Ther 1(1):7–37 discussion 37PubMed
89.
Frondoza CG et al (2004) An in vitro screening assay for inhibitors of proinflammatory mediators in herbal extracts using human synoviocyte cultures. In Vitro Cell Dev Biol Anim 40(3–4):95–101PubMed
90.
Deodhar SD, Sethi R, Srimal RC (1980) Preliminary study on antirheumatic activity of curcumin (diferuloyl methane). Indian J Med Res 71:632–634PubMed
91.
Tohda C et al (2006) Comparison of anti-inflammatory activities of six curcuma rhizomes: a possible curcuminoid-independent pathway mediated by Curcuma phaeocaulis extract. Evid Based Complement Alternat Med 3(2):255–260PubMed
92.
Afzal M et al (2001) Ginger: an ethnomedical, chemical and pharmacological review. Drug Metabol Drug Interact 18(3–4):159–190PubMed
93.
Ippoushi K (2003) [6]-Gingerol inhibits nitric oxide synthesis in activated J774.1 mouse macrophages and prevents peroxynitrite-induced oxidation and nitration reactions. Life Sci 73(26):3427–3437PubMed
94.
Jolad SD et al (2004) Fresh organically grown ginger (Zingiber officinale): composition and effects on LPS-induced PGE2 production. Phytochemistry 65(13):1937–1954PubMed
95.
Srivastava KC, Mustafa T (1992) Ginger (Zingiber officinale) in rheumatism and musculoskeletal disorders. Med Hypotheses 39(4):342–348PubMed
96.
Srivastava KC, Mustafa T (1989) Ginger (Zingiber officinale) and rheumatic disorders. Med Hypotheses 29(1):25–28PubMed
97.
Altman RD, Marcussen KC (2001) Effects of a ginger extract on knee pain in patients with osteoarthritis. Arthritis Rheum 44(11):2531–2538PubMed
98.
Bliddal H et al (2000) A randomized, placebo-controlled, cross-over study of ginger extracts and ibuprofen in osteoarthritis. Osteoarthritis Cartilage 8(1):9–12PubMed
99.
Ramprasath VR, Shanthi P, Sachdanandam P (2006) Effect of Semecarpus anacardium Linn. nut milk extract on rat neutrophil functions in adjuvant arthritis. Cell Biochem Funct 24(4):333–340PubMed
100.
Ramprasath VR, Shanthi P, Sachdanandam P (2006) Immunomodulatory and anti-inflammatory effects of Semecarpus anacardium LINN. Nut milk extract in experimental inflammatory conditions. Biol Pharm Bull 29(4):693–700PubMed
101.
Vijayalakshmi T, Muthulakshmi V, Sachdanandam P (1996) Effect of the milk extract of Semecarpus anacardium nut on adjuvant arthritis—a dose-dependent study in Wistar albino rats. Gen Pharmacol 27(7):1223–1226PubMed
102.
Vijayalakshmi T, Muthulakshmi V, Sachdanandam P (1997) Salubrious effect of Semecarpus anacardium against lipid peroxidative changes in adjuvant arthritis studied in rats. Mol Cell Biochem 175(1–2):65–69PubMed
103.
Ravichandran LV, Puvanakrishnan R, Joseph KT (1990) Alterations in the heart lysosomal stability in isoproterenol induced myocardial infarction in rats. Biochem Int 22(2):387–396PubMed
104.
Denner SS (2007) A review of the efficacy and safety of devil’s claw for pain associated with degenerative musculoskeletal diseases, rheumatoid, and osteoarthritis. Holist Nurs Pract 21(4):203–207PubMed
105.
Jeon HJ et al (2008) Anti-inflammatory activity of Taraxacum officinale. J Ethnopharmacol 115(1):82–88PubMed
106.
Cleland LG, James MJ, Proudman SM (2006) Fish oil: what the prescriber needs to know. Arthritis Res Ther 8(1):202PubMed
107.
Calder PC (2006) n-3 polyunsaturated fatty acids, inflammation, and inflammatory diseases. Am J Clin Nutr 83(6 Suppl):1505S–1519SPubMed
108.
De Caterina R, Massaro M (2005) Omega-3 fatty acids and the regulation of expression of endothelial pro-atherogenic and pro-inflammatory genes. J Membr Biol 206(2):103–116PubMed
109.
Novak TE et al (2003) NF-kappa B inhibition by omega -3 fatty acids modulates LPS-stimulated macrophage TNF-alpha transcription. Am J Physiol Lung Cell Mol Physiol 284(1):L84–L89PubMed
110.
Zhao Y et al (2004) Eicosapentaenoic acid prevents LPS-induced TNF-alpha expression by preventing NF-kappaB activation. J Am Coll Nutr 23(1):71–78PubMed
111.
Adam O et al (2003) Anti-inflammatory effects of a low arachidonic acid diet and fish oil in patients with rheumatoid arthritis. Rheumatol Int 23(1):27–36PubMed
112.
Goldberg RJ, Katz J (2007) A meta-analysis of the analgesic effects of omega-3 polyunsaturated fatty acid supplementation for inflammatory joint pain. Pain 129(1–2):210–223PubMed
113.
Galarraga B et al (2008) Cod liver oil (n-3 fatty acids) as an non-steroidal anti-inflammatory drug sparing agent in rheumatoid arthritis. Rheumatology (Oxford) 47(5):665–669
114.
Berbert AA et al (2005) Supplementation of fish oil and olive oil in patients with rheumatoid arthritis. Nutrition 21(2):131–136PubMed
115.
Ozturk HS et al (1999) Oxidant/antioxidant status of plasma samples from patients with rheumatoid arthritis. Rheumatol Int 19(1–2):35–37PubMed
116.
Tappel AL (1973) Lipid peroxidation damage to cell components. Fed Proc 32(8):1870–1874PubMed
117.
Halliwell B, Hoult JR, Blake DR (1988) Oxidants, inflammation, and anti-inflammatory drugs. FASEB J 2(13):2867–2873PubMed
118.
Jaswal S et al (2003) Antioxidant status in rheumatoid arthritis and role of antioxidant therapy. Clin Chim Acta 338(1–2):123–129PubMed
119.
Kalavacherla US et al (1994) Malondialdehyde as a sensitive marker of inflammation in patients with rheumatoid arthritis. J Assoc Physicians India 42(10):775–776PubMed
120.
Gambhir JK, Lali P, Jain AK (1997) Correlation between blood antioxidant levels and lipid peroxidation in rheumatoid arthritis. Clin Biochem 30(4):351–355PubMed
121.
Chaturvedi V et al (1999) Estimation & significance of serum & synovial fluid malondialdehyde levels in rheumatoid arthritis. Indian J Med Res 109:170–174PubMed
122.
van Vugt RM et al (2008) Antioxidant intervention in rheumatoid arthritis: results of an open pilot study. Clin Rheumatol 27(6):771–775PubMed
123.
Selvam R et al (2007) Low frequency and low intensity pulsed electromagnetic field exerts its antiinflammatory effect through restoration of plasma membrane calcium ATPase activity. Life Sci 80(26):2403–2410PubMed
124.
Kumar VS et al (2005) Optimization of pulsed electromagnetic field therapy for management of arthritis in rats. Bioelectromagnetics 26(6):431–439PubMed
125.
Almaden Y et al (2002) Regulation of arachidonic acid production by intracellular calcium in parathyroid cells: effect of extracellular phosphate. J Am Soc Nephrol 13(3):693–698PubMed
126.
Segal NA et al (2001) Two configurations of static magnetic fields for treating rheumatoid arthritis of the knee: a double-blind clinical trial. Arch Phys Med Rehabil 82(10):1453–1460PubMed
127.
Werneke U et al (2004) Potential health risks of complementary alternative medicines in cancer patients. Br J Cancer 90(2):408–413PubMed
128.
Sundrarjun T et al (2004) Effects of n-3 fatty acids on serum interleukin-6, tumour necrosis factor-alpha and soluble tumour necrosis factor receptor p55 in active rheumatoid arthritis. J Int Med Res 32(5):443–454PubMed
Metadata
Title
Complementary and alternative medicine use in rheumatoid arthritis: proposed mechanism of action and efficacy of commonly used modalities
Authors
Petros Efthimiou
Manil Kukar
Publication date
01-03-2010
Publisher
Springer-Verlag
Published in
Rheumatology International / Issue 5/2010
Print ISSN: 0172-8172
Electronic ISSN: 1437-160X
DOI
https://doi.org/10.1007/s00296-009-1206-y

Other articles of this Issue 5/2010

Rheumatology International 5/2010 Go to the issue

Original Article

Association of chronic non-bacterial osteomyelitis with Crohn’s disease but not with CARD15 gene variants

Case Report

Infliximab for reactive arthritis secondary to Chlamydia trachomatis infection

Original Article

Erdheim-Chester disease: a case report with pulmonary, kidney involvement and bone lesions

Case Report

Childhood cutaneous polyarteritis nodosa: an unusual presentation

Original Article

Lower bone mineral density of forearm in postmenopausal patients with radiographic hand osteoarthritis

Original Article

The association of HLA-B*27 subtypes with ankylosing spondylitis in Wuhan population of China
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits